(W3) The Role of Reinsurance and Stop-Loss Programs in Managing High-Investment Medications

The promise of cell and gene therapies as a means to cure rare conditions is exciting for health care providers and patients alike. It is well-known that these therapies may also come at a significant cost—hence the term “high-investment medications.”

While many innovative strategies have been discussed, more data and experience are needed before these models can be fully implemented. Some organizations have turned to reinsurance and stop-loss programs to help offset the risk posed by “high investment medications” and other types of catastrophic coverage needs.

This session will provide a deep dive into reinsurance and stop-loss coverage. How do these programs work? What are the common trends seen with this type of coverage? What organizations tend to use this type of coverage and why? Come join this session as experts delve into the practicality of reinsurance and stop-loss coverage.